REMINDER: Our focusIR Investor Webinar takes place TONIGHT with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLitigation Cap. Regulatory News (LIT)

Share Price Information for Litigation Cap. (LIT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 117.00
Bid: 115.00
Ask: 116.00
Change: -2.50 (-2.09%)
Spread: 1.00 (0.87%)
Open: 118.00
High: 118.00
Low: 117.00
Prev. Close: 119.50
LIT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

New US$50m Credit Facility

22 Feb 2021 07:00

RNS Number : 8087P
Litigation Capital Management Ltd
22 February 2021
 

 

 

22 February 2021

 

Litigation Capital Management Limited

("LCM" or the "Company")

 

New US$50m Credit Facility

 

 

Litigation Capital Management Limited (AIM:LIT), a leading alternate asset manager of disputes financing solutions, is pleased to announce that it has secured a US$50 million credit facility (the "Credit Facility") with Northleaf Capital Partners ("Northleaf") to provide the Company with additional investment capital. Northleaf is a global private markets investment firm, with experience in the litigation finance sector.

The Credit Facility provides LCM with significant additional capital flexibility to enable the Company to grow its direct investment portfolio, its asset management business and to supplement balance sheet capital in relation to the co-funding opportunities of the LCM Global Alternative Returns Fund launched last year (the "GAR Fund").

The Credit Facility, which is secured against LCM's assets, is available for general corporate purposes, and has an overall term of four years. The coupon comprises a LIBOR based rate of 8% per annum together with a profit participation calculated by reference to the profitability of LCM's direct investments. In all circumstances, the overall cost of the facility is capped at 13% per annum. The Credit Facility can be drawn down during the first two years of the facility. The facility otherwise contains the usual financial covenants and reporting conditions of a facility of this nature.

Patrick Moloney, CEO of LCM, commented: "The securing of this Credit Facility is a hugely significant development in LCM's growth. The Credit Facility, together with LCM's existing resources, provides LCM with flexible capital structure for the foreseeable future to meet our most conservative assessment of the expected demand for LCM's litigation finance needs, as well as LCM's GAR Fund co-funding obligations, including any anticipated potential upsizing."

Jonathan Moulds, Chairman of LCM, commented: "The Board is delighted to partner with Northleaf, a high calibre capital provider with a presence in our major markets and deep expertise in litigation funding, at a time when LCM is witnessing an uplift in litigation finance applications as a result of a number of factors including the extraordinary uncertainty facing global economies. These conditions, combined with the flexibility the Credit Facility, provides LCM with an excellent opportunity to accelerate growth."

 

Enquiries

 

Litigation Capital Management

c/o Alma PR 

Patrick Moloney, Chief Executive Officer

Canaccord (Nomad and Joint Broker) 

Tel: 020 7523 8000

Bobbie Hilliam

Investec Bank plc (Joint Broker)

Tel: 020 7597 5970

David Anderson

Alma PR

Tel: 020 3405 0205

Justine James

Susie Hudson

Kieran Breheny

LCM@almapr.co.uk

 

 

NOTES TO EDITORS

 

Litigation Capital Management (LCM) is an alternate asset manager specialising in disputes financing solutions internationally, which operates two business models. The first is direct investments made from LCM's permanent balance sheet capital and the second is third party fund management. Under those two business models, LCM currently pursues three investment strategies: Single-case funding, Portfolio funding and Acquisitions of claims. LCM generates its revenue from both its direct investments and also performance fees through asset management.

LCM has an unparalleled track record driven by disciplined project selection and robust risk management.

Currently headquartered in Sydney, with offices in London, Singapore, Brisbane and Melbourne, LCM listed on AIM in December 2018, trading under the ticker LIT.

www.lcmfinance.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCGCGDDSDDDGBB
Date   Source Headline
14th May 20247:00 amRNSTransaction in Own Shares
13th May 20247:00 amRNSTransaction in Own Shares
10th May 20247:00 amRNSTransaction in Own Shares
9th May 20247:00 amRNSTransaction in Own Shares
7th May 20247:00 amRNSTransaction in Own Shares
3rd May 20247:00 amRNSTransaction in Own Shares
2nd May 20247:00 amRNSTransaction in Own Shares
1st May 20247:00 amRNSTransaction in Own Shares
26th Apr 20247:00 amRNSTransaction in Own Shares
24th Apr 20247:00 amRNSTransaction in Own Shares
22nd Apr 20247:00 amRNSTransaction in Own Shares
18th Apr 20247:00 amRNSTransaction in Own Shares
17th Apr 20247:00 amRNSTransaction in Own Shares
16th Apr 20247:00 amRNSTransaction in Own Shares
12th Apr 20247:00 amRNSTransaction in Own Shares
11th Apr 20247:00 amRNSTransaction in Own Shares
10th Apr 20247:00 amRNSTransaction in Own Shares
9th Apr 20247:00 amRNSTransaction in Own Shares
8th Apr 20247:00 amRNSTransaction in Own Shares
5th Apr 20247:00 amRNSTransaction in Own Shares
3rd Apr 20247:00 amRNSTransaction in Own Shares
28th Mar 20247:00 amRNSTransaction in Own Shares
27th Mar 20247:00 amRNSTransaction in Own Shares
26th Mar 20247:00 amRNSTransaction in Own Shares
25th Mar 20247:00 amRNSTransaction in Own Shares
22nd Mar 20247:00 amRNSTransaction in Own Shares
21st Mar 20247:00 amRNSTransaction in Own Shares
20th Mar 20247:00 amRNSTransaction in Own Shares
19th Mar 20247:01 amRNSTransaction in Own Shares
19th Mar 20247:00 amRNSInterim results for the HY ended 31 December 2023
18th Mar 20247:00 amRNSTransaction in Own Shares
15th Mar 20247:00 amRNSTransaction in Own Shares
14th Mar 20247:00 amRNSTransaction in Own Shares
13th Mar 20247:00 amRNSTransaction in Own Shares
12th Mar 20247:00 amRNSTransaction in Own Shares
11th Mar 20247:00 amRNSTransaction in Own Shares
8th Mar 20247:00 amRNSTransaction in Own Shares
7th Mar 20247:00 amRNSTransaction in Own Shares
6th Mar 20247:00 amRNSTransaction in Own Shares
5th Mar 20247:00 amRNSTransaction in Own Shares
4th Mar 20247:00 amRNSTransaction in Own Shares
1st Mar 20247:00 amRNSTransaction in Own Shares
29th Feb 20247:00 amRNSTransaction in Own Shares
28th Feb 20247:00 amRNSTransaction in Own Shares
27th Feb 20247:00 amRNSTransaction in Own Shares
26th Feb 20247:00 amRNSTransaction in Own Shares
23rd Feb 20247:00 amRNSTransaction in Own Shares
22nd Feb 20247:00 amRNSTransaction in Own Shares
21st Feb 20247:00 amRNSTransaction in Own Shares
20th Feb 20247:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.